کد مقاله کد نشریه سال انتشار مقاله انگلیسی نسخه تمام متن
2402276 1102741 2014 6 صفحه PDF دانلود رایگان
عنوان انگلیسی مقاله ISI
The effectiveness of the polysaccharide pneumococcal vaccine for the prevention of hospitalizations due to Streptococcus pneumoniae community-acquired pneumonia in the elderly differs between the sexes: Results from the Community-Acquired Pneumonia Organi
ترجمه فارسی عنوان
اثربخشی واکسن پنوموکوک پلی ساکارید برای جلوگیری از بستری شدن در بیماران مبتلا به پنومونی ناشی از استرپتوکوک پنومونیه در افراد مسن بین جنس ها متفاوت است: نتایج حاصل از ارگانهای پنومونی در جامعه
کلمات کلیدی
موضوعات مرتبط
علوم زیستی و بیوفناوری ایمنی شناسی و میکروب شناسی ایمونولوژی
چکیده انگلیسی


• We modeled the effectiveness of a pneumococcal vaccine for patients with pneumonia.
• Prevention of hospitalization due to Streptococcus pneumoniae pneumonia was modeled.
• The effectiveness of the polysaccharide pneumococcal vaccine was 37% (P = 0.01).
• However, the overall effectiveness was driven by sex differences.
• The vaccine was effective in females (68%, P = 0.001) but not in males (34%, P = 0.06).

BackgroundThe effectiveness of the 23-valent pneumococcal polysaccharide vaccine (PPV23) to prevent hospitalizations due to Streptococcus pneumoniae community-acquired pneumonia (SpCAP) is controversial. Recent literature suggests that vaccine effectiveness may be influenced by sex. In this study, we define the effectiveness of prior PPV23 vaccination for the prevention of hospitalizations due to SpCAP, and evaluate the impact of sex on this effectiveness.MethodsThis was a nested case–control study from the CAPO international cohort study database. SpCAP was defined as CAP plus S. pneumoniae identified in blood, bronchoalveolar lavage, sputum, or urinary antigen. Vaccination with PPV23 prior to hospitalization was defined as documented in the medical record. A propensity score-weighted logistic regression model was used to calculate odds ratios. The adjusted vaccine effectiveness (aVE) was calculated as 1-adjusted odds ratio.ResultsFrom a total of 2688 elderly adult hospitalized patients with CAP, SpCAP was identified in 279 (10%). The overall aVE was 37% (95% CI: 10.1–55.4%, P = 0.01). For males, the aVE was 34% (95% CI:−1.0% to 57.3%, P = 0.06). For females the aVE was 68% (95% CI: 40.3–83.0%, P = 0.001).ConclusionsPPV23 protects elderly patients from hospitalization due to SpCAP, but female sex drives the effectiveness. Future analysis of vaccine trials should consider the importance of sex as a stratification factor.

ناشر
Database: Elsevier - ScienceDirect (ساینس دایرکت)
Journal: Vaccine - Volume 32, Issue 19, 17 April 2014, Pages 2198–2203
نویسندگان
, , , , , , , , , , ,